220 related articles for article (PubMed ID: 35027011)
1. Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study.
Takamizawa S; Shimoi T; Satomi-Tsushita N; Yazaki S; Okuya T; Kojima Y; Sumiyoshi-Okuma H; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Yonemori K
BMC Cancer; 2022 Jan; 22(1):64. PubMed ID: 35027011
[TBL] [Abstract][Full Text] [Related]
2. Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel.
Miyagawa Y; Araki K; Bun A; Ozawa H; Fujimoto Y; Higuchi T; Nishimukai A; Kira A; Imamura M; Takatsuka Y; Miyoshi Y
Clin Breast Cancer; 2018 Oct; 18(5):400-409. PubMed ID: 29605174
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Nutritional Index Is Superior to Neutrophil-to-lymphocyte Ratio as a Prognostic Marker in Metastatic Breast Cancer Patients Treated With Eribulin.
Oba T; Maeno K; Ono M; Ito T; Kanai T; Ito KI
Anticancer Res; 2021 Jan; 41(1):445-452. PubMed ID: 33419842
[TBL] [Abstract][Full Text] [Related]
4. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.
Kaufman PA; Awada A; Twelves C; Yelle L; Perez EA; Velikova G; Olivo MS; He Y; Dutcus CE; Cortes J
J Clin Oncol; 2015 Feb; 33(6):594-601. PubMed ID: 25605862
[TBL] [Abstract][Full Text] [Related]
5. Utility of Follow-up With Absolute Lymphocyte Count in Patients Undergoing Eribulin Treatment for Early Detection of Progressive Advanced or Metastatic Breast Cancer.
Goto W; Kashiwagi S; Takada K; Asano Y; Morisaki T; Shibutani M; Tanaka H; Hirakawa K; Ohira M
Anticancer Res; 2022 Feb; 42(2):939-946. PubMed ID: 35093893
[TBL] [Abstract][Full Text] [Related]
6. Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer.
Chabot I; Zhao Q; Su Y
Curr Med Res Opin; 2020 Dec; 36(12):2025-2036. PubMed ID: 33044090
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil-to-lymphocyte ratio and histological type might predict clinical responses to eriburin-based treatment in patients with metastatic breast cancer.
Myojin M; Horimoto Y; Ito M; Kitano S; Ishizuka Y; Sasaki R; Uomori T; Himuro T; Murakami F; Nakai K; Iijima K; Saito M
Breast Cancer; 2020 Jul; 27(4):732-738. PubMed ID: 32108306
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness analysis of monotherapy with cytotoxic agents in triple-negative metastatic breast cancer in a community setting.
Dranitsaris G; Gluck S; Faria C; Cox D; Rugo H
Clin Ther; 2015 Jan; 37(1):134-44. PubMed ID: 25433768
[TBL] [Abstract][Full Text] [Related]
9. Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue Sarcoma.
Sato Y; Nakano K; Fukuda N; Wang X; Urasaki T; Ohmoto A; Yunokawa M; Ono M; Tomomatsu J; Hayakawa K; Funauchi Y; Tanizawa T; Ae K; Matsumoto S; Takahashi S
Anticancer Res; 2021 Jan; 41(1):527-532. PubMed ID: 33419852
[TBL] [Abstract][Full Text] [Related]
10. Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.
Yardley DA; Reeves J; Dees EC; Osborne C; Paul D; Ademuyiwa F; Soliman H; Guthrie T; Andersen J; Krekow L; Choksi J; Daniel B; Danso M; Favret A; Oommen S; Brufsky A; Bromund JL; Lin Y; Ibrahim AB; Richards PD
Clin Breast Cancer; 2016 Dec; 16(6):471-479.e1. PubMed ID: 27569274
[TBL] [Abstract][Full Text] [Related]
11. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.
Twelves C; Cortes J; Vahdat LT; Wanders J; Akerele C; Kaufman PA
Clin Breast Cancer; 2010 Apr; 10(2):160-3. PubMed ID: 20299316
[TBL] [Abstract][Full Text] [Related]
12. Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine.
Pivot X; Im SA; Guo M; Marmé F
Breast Cancer; 2018 May; 25(3):370-374. PubMed ID: 29302858
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
Cortes J; Vahdat L; Blum JL; Twelves C; Campone M; Roché H; Bachelot T; Awada A; Paridaens R; Goncalves A; Shuster DE; Wanders J; Fang F; Gurnani R; Richmond E; Cole PE; Ashworth S; Allison MA
J Clin Oncol; 2010 Sep; 28(25):3922-8. PubMed ID: 20679609
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
Ates O; Babacan T; Kertmen N; Sarici F; Cenoli A; Akin S; Karakas Y; Kilickap S; Ozisik Y; Sever AR; Aksoy S; Altundag K
J BUON; 2016; 21(2):375-81. PubMed ID: 27273947
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan.
Lin YJ; Kuo CN; Ko Y
Breast; 2021 Jun; 57():18-24. PubMed ID: 33706025
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
McIntyre K; O'Shaughnessy J; Schwartzberg L; Glück S; Berrak E; Song JX; Cox D; Vahdat LT
Breast Cancer Res Treat; 2014 Jul; 146(2):321-8. PubMed ID: 24699910
[TBL] [Abstract][Full Text] [Related]
17. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
Cortes J; O'Shaughnessy J; Loesch D; Blum JL; Vahdat LT; Petrakova K; Chollet P; Manikas A; Diéras V; Delozier T; Vladimirov V; Cardoso F; Koh H; Bougnoux P; Dutcus CE; Seegobin S; Mir D; Meneses N; Wanders J; Twelves C;
Lancet; 2011 Mar; 377(9769):914-23. PubMed ID: 21376385
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.
Hayashida T; Jinno H; Mori K; Sato H; Matsui A; Sakurai T; Hattori H; Takayama S; Wada M; Takahashi M; Seki H; Seki T; Nagayama A; Matsumoto A; Kitagawa Y
BMC Cancer; 2018 Jun; 18(1):701. PubMed ID: 29954362
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety evaluation of eribulin-trastuzumab combination therapy with heavily pretreated HER2-positive metastatic breast cancer.
Sarici F; Altundag K
J BUON; 2020; 25(6):2562-2569. PubMed ID: 33455097
[TBL] [Abstract][Full Text] [Related]
20. A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting.
Dranitsaris G; Beegle N; Kalberer T; Blau S; Cox D; Faria C
J Oncol Pharm Pract; 2015 Jun; 21(3):170-7. PubMed ID: 24620009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]